Yuklanmoqda
x
Ushbu veb-sayt muhim cookie-fayllardan foydalanadi. Sizning roziligingiz bilan biz statistika uchun Google Analytics cookie-fayllarini joylashtiramiz.

uchun cookie siyosati Slzii.com

Bu Cookie siyosati Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

Qidirmoq (Yangiliklar)

Niderlandiya | Belgiya | Kyurasao | Tailand | Nigeriya | Germaniya | Ispaniya | Meksika | Kolumbiya | Venesuela | Argentina | Urugvay | Chili | Ekvador | Puerto-Riko | Peru | Kuba | Boliviya | Kosta-Rika | Dominika Respublikasi | El Salvador | Gvatemala | Gonduras | Nikaragua | Paragvay | Panama | Fransiya | Kot-d'Ivuar | Monako | Kamerun | Kongo Respublikasi | Gabon | Senegal | Benin | Misr | Birlashgan Arab Amirliklari | Qatar | Saudiya Arabistoni | Marokash | Iroq | Tunis | Sudan | Yaman | Bahrayn | Eron | Braziliya | Portugaliya | Islandiya | Norvegiya | Xitoy | Tayvan | Gonkong | Aomin | Isroil | Nepal | Chex Respublikasi | Polsha | Italiya | Bangladesh | Vetnam | kurka | Malayziya | Bruney | Janubiy Koreya | Shimoliy Koreya | Indoneziya | Yaponiya | Hindiston | Rossiya | Filippin | Ukraina | Shveytsariya | Finlyandiya | Lyuksemburg | Irlandiya | Estoniya | Ruminiya | Bolgariya | Qo'shma Shtatlar | Keniya | Kipr | Gretsiya | Lixtenshteyn | Uganda | Shvetsiya | Buyuk Britaniya | Niger | Pokiston | Mo'g'uliston | Falastin | Armaniston | Avstriya | Avstraliya | Kanada | Daniya | Jazoir | Gana | Xorvatiya | Vengriya | Kambodja | Shri-Lanka | Litva | Latviya | Malta | Yangi Zelandiya | Seyshel orollari | Singapur | Slovakiya | Janubiy Afrika | Andorra | Zambiya | Mavrikiy | Tanzaniya | Britaniya Virjiniya orollari | Bormoq | Ozarbayjon | Moldova | Sloveniya | Beliz | Qozog'iston | Qirg'iziston | Serbiya | O'zbekiston | Belarusiya | Gvineya | Gruziya | Bosniya va Gertsegovina | Iordaniya | Quvayt | Kosovo | Albaniya | Mozambik | Afg'oniston | Tojikiston | Chernogoriya | Liviya | Kongo-Kinshasa | Livan | Zimbabve | Suriya | Mali | Butan | Ekvatorial Gvineya | Ruanda | Malavi | Myanma | Botsvana | Shimoliy Makedoniya | Burundi | Yamayka | Efiopiya | Yangi Kaledoniya | Syerra-Leone | Namibiya | Laos | Timor-Sharqiy | Maldiv orollari | Gaiti | Burkina-Faso | Ummon | Bagama orollari | Somali | Barbados | Grenada | Papua-Yangi Gvineya | Jersi | Fiji | San-Marino | Fransuz Polineziyasi | Trinidad va Tobago | Surinam | Lesoto | Eritreya | Sent-Lyusiya | Kayman orollari | Angola | Gambiya | Svazilend | Madagaskar | Liberiya | Mavritaniya | Gayana | Vanuatu | Chad | Tonga | Bermud orollari | Turkmaniston | Samoa | Jibuti | Komor orollari | Vatikan shahri | Palau | Dominika | Kabo-Verde | Markaziy Afrika Respublikasi | Solomon orollari | Tuvalu | Sint-Marten |
OpenAI 与美国战争部达成协议引发用户抵制,“取消 ChatGPT”运动蔓延
IT之家 3 月 1 日消息,人工智能领域竞争激烈,多家公司争夺用户关注(最终是用户的钱包)。尽管 ChatGPT 已成为人工智能领域家喻户晓的名字,但权力格局可能正在发生转变,一场“取消 ChatGPT”的运动正引发关注。OpenAI 首席执行官萨姆 · 奥尔特曼昨晚在 X 平台发文称,其公司已与美国战争部达成协议,“将我们的模型部署到他们的机密网络中”。他还表示:“在所有沟通中,战争部都表现出对安全的高度重视,以及希望通过合作实现最佳结果的意愿。”IT之家注意到,奥尔特曼称:“我们仍将致力于尽最大努力服务全人类。世界复杂、混乱,有时甚至充满危险。”他还声称:“我们也会构建技术安全措施,确保模型正常运行,这也是战争部所希望的。”但用户似乎并不愿意轻易相信他的说法,这也情有可原。此前,OpenAI 刚与竞争对手 Anthropic 一同表态,拒绝将产品用于大规模国内监控或全自动武器研发。Anthropic 在一篇博客文章中指出:“战争部已表示,只会与同意接受‘任何合法用途’、并在上述场景中取消安全限制的人工智能公司签约。”而奥尔特曼的发文暗示,OpenAI 接受政府使用其工具。根据《爱国者法案》的部分条款,这在某些情况下极易演变为针对美国公民的大规模监控,名义上却是为了监控外国人员。因此,用户选择了唯一能真正打击 OpenAI 的方式:用脚投票,停止付费。据 Tom's Guide 报道,“取消 ChatGPT(Cancel ChatGPT)”的运动正在蔓延,似乎已经影响到这家人工智能巨头的收入。当然,取消订阅的实际规模难以估量,可能只是在 Reddit 和 X 上发声的少数人,而绝大多数 ChatGPT 用户仍在正常使用,全然不知自己的数据可能会被战争部使用。尽管眼下 OpenAI 成为网络众矢之的(Anthropic 则收获一片好评),但值得注意的是,默许人工智能服务被用于潜在监控和自主武器的,并非只有 OpenAI 一家。例如,谷歌去年从内部规定中删除了对相关技术的明确禁令,让其 Gemini 模型存在被此类用途使用的可能。亚马逊在相关文档中也只给出了模糊的“负责任使用”表述。
2026-03-01 05:29:04

'HK prepared for market swings due to Mideast war'
Financial Secretary Paul Chan on Sunday said that Hong Kong had sufficient contingency plans regarding the financial turbulence expected from the war in the Middle East. He said the SAR doesn't have much direct trade and investment with Iran, but the conflict brought about significant uncertainties to the world. The minister said on a TVB programme that Hong Kong is prepared for market fluctuations, and even potential capital inflows from the Middle East."For example, there'll be rather big fluctuations in financial markets. Capital flow changes might be quicker and uncertain. There could be some capital from that region that wants to come to safe havens such as Hong Kong," Chan said. "We'll handle financial risks and fluctuations very carefully, we have made sufficient contingency plans."The minister added that officials would keep assessing the potential rises in transportation costs for international trade, as well as gold and crude oil prices. Meanwhile, Chan said the government's plans to use HK$150 billion from the Exchange Fund as a kick-start investment in the Northern Metropolis, because it sees the project as an investment in the future."We do invest a lot in the metropolis. But we're certainly not putting everything in one basket," he said."In recent years and going forward, one of the areas we have to work hard in is to attract more outside companies to come to Hong Kong."The minister said Hong Kong needs to enrich its depth as a global financial centre by attracting more tourists and people doing business here.He said tax returns from the Northern Metropolis were expected in four to five years.As to whether the government plans to widen the tax base in Hong Kong, Chan said officials have studied relevant ideas and have proposals in mind. The minister stressed, however, that from the present social standpoint, the current-term administration wants to focus on economic development.He also emphasised that the SAR's simple tax system remains a core competitive advantage globally.Edited by Tony Sabine
2026-03-01 05:24:20

First Mold Achieves Breakthrough Growth Through Amoeba Management, Driving Precision Manufacturing and Rapid Delivery Excellence
ZHONGSHAN, China, Feb. 26, 2026 /PRNewswire/ -- First Mold held its annual general meeting on February 25th, focusing on how best to share departments' accomplishments. The main agenda of the meeting was to evaluate the company's success in the past six months of implementing the Amoeba Management model. The model was implemented in the company's Injection Molding Process Department and organized into different units. Initially, the implementation of this model began as a structural transformation. However, the deliberations from the meeting found that the model has contributed to tangible financial growth. It had also led to operational efficiency, enhancing customer satisfaction. Breakthrough Progress in Precision Manufacturing The adoption of the Amoeba units over the past six months has significantly contributed to reforming injection molding. During the meeting, it was realized that every Amoeba unit recorded net profit growth over the past six months, indicating a cumulative profit growth for the First Mold company. In the meeting, Hui He, the leader of the Mold Manufacturing Amoeba, said, "Our manufacturing unit has been receiving more demand. Sales have been increasing over the past six months compared to when we did not adopt the Amoeba model. Interestingly, we significantly reduced the cost of manufacturing and recorded minimal waste". This implies that the company's organization into Amoeba models not only increased sales but also reduced waste, thereby increasing net profits. Overall, the restructuring of First Mold into these Amoeba units has enabled the company to micromanage distinct product systems, thereby improving its precision mold making capabilities. The company currently enjoys enhanced efficiency in its custom injection molding services, offering the best quality to its broader customer base while meeting required targets. Background and Motivation for Change First Mold did not choose to shift to Amoeba Management on its own. The company had experienced some level of pressure before rethinking and adopting the model. In its efforts to expand operations and reach new markets, First Mold has experienced increasing global demand for diverse needs. First, the customers have demanded small-batch, high-variety productions. For instance, the company has been experiencing an abrupt increase in the supply of consumer electronics molds for about 2 months before the demand falls off. Integrating such production in their systems has been proven challenging. Thus, they have found it better to develop smaller units that can deal with such specific demands. The other key drivers from customers included rapid tooling development, shorter lead times, and strict cost control. Initially, the structures at First Mold were inefficient at fulfilling these demands. The systems faced challenges, including slow cycle times, leading to supply backlogs. They further had limited cost transparency. In essence, there was minimal supervision and material selection, which sometimes led to costly production. Some projects require seamless coordination between design and machining. These injection molding requirements were not integrated into the traditional systems, thus leading to inefficiencies. Because of these ineffective systems, the company experiences an influx of customer feedback demanding improvement. First, the majority of the customers demanded faster response in quick-turn injection molding. Others demanded flexibility in low volume injection molding services. Yet another set of customers wanted stronger support for small batch production. These responses prompted the company to adopt a well-stabilized approach to meeting customers' demand. Amoeba Implementation Framework Biologically, an amoeba is a single-celled organism that operates independently of other cells. The selection of the term "Amoeba" by First Mold was basically to imply that every subsidiary at the company was to deal independently with the specific company's Injection Molding Process. The three core amoebae include Three Core Amoebas include Mold & Injection Project Amoeba led by Qing Xu, Mold Design Amoeba led by Tian Lv, and Mold Manufacturing Amoeba led by Hui He. The following are the other nine specialized amoebae. Amoeba Leader Production Mold Assembly Jin Zhou Rapid Tool Assembly Ryu Feng Mold Polishing Lin Wang Grinding Hua Deng CNC Machining Thunder River EDM De Hua Process Engineering Chi Chen Mold Warehouse Yu Li Mold Repair Guang Zhong Interestingly, First Mold gave autonomy, allowing them to account for their operations, determine their operating costs, and calculate their independent profits. There is a cross-unit collaboration among different Amoebas where needed. For instance, mold optimization, Amoeba, and rapid tooling. Amoeba directly interacts with CNC machining to enhance faster design-to-production. Leadership Perspectives Different leaders have held different views on implementing the Amoeba models at First Mold. The majority believe that the model is a game-changer in organizational operations, improving the company's effectiveness. For example, the CEO, James Li, believes that, in addition to accelerating the company's rapid injection molding, the model has led to the emergence of different leaders in the organization with a strong business ownership mindset. "I didn't know we had great leaders in our companies. This model has encouraged an independent mindset among different leaders. We have recorded an increase in organizational profits due to the diversification of leadership skills. Amoeba model has made every manufacturing unit in our company accountable for the costs and revenues. We currently have a team of leaders in which managers own their responsibilities. They currently own the business and do not serve as servants of First Mold. With this trend, we project First Mold even growing beyond its boundaries." The production director, Bowen Huang, had also concurred with the CEO that Amoebas had indeed contributed immensely to First Mold's success. The director notes that Amoeba has led to significant gains in the injection molding optimization. The model has expertise in mold design optimization, improving production efficiency. "We faced numerous challenges in the injection molding that, at some point, led to the losses. Sometimes we couldn't source materials on time, leading to delays in production, which would be reflected in deadline failures." According to Bowen Huang, the Amoeba model shows that operational metrics indicate improved injection cycle stability. The sales director, Young Lee, realized there was positive customer feedback. The customers had noted 30% reduction in delivery time. The model eliminated the initial cross-departmental coordination required by the traditional model. This extensive coordination contributed to a series of delays. With the adoption of the Amoeba model, the units collaborate seamlessly. According to Young Lee, customers noted faster project quoting, a high response rate, and a faster design-to-production period. Measurable Results After Six Months Category Metric Improvement / Outcome Operational Impact EfficiencyMetrics Average Delivery Lead Time ↓ 30% Faster project turnaround and improved on-time delivery Mold Trial Completion Speed ↑ 22% faster Reduced time-to-productionand fewer iteration cycles Production Scheduling Efficiency ↑ 18% improvement Better machine utilization and workflow coordination Quality Metrics Defect Rate ↓ 15% Higher product reliability and reduced rework costs First-Pass Yield (Injection Trials) Increased (measurableupward trend) Improved process stability and mold optimization Dimensional Consistency Improved in high precision plastic components Enhanced tolerance control andrepeatability FinancialMetrics Amoeba Unit Profitability Multiple units achievednet profit growth Strengthened internal accountability and revenue performance Cost Transparencyper Project Significantly enhanced Accurate cost tracking and pricing optimization Waste & Idle Resource Allocation Reduced Leaner operations and improved cost efficiency Customer Metrics Repeat Order Rate Increased Higher customer retention CustomerSatisfaction Scores Improved Stronger brand trust and service reliability Case Study: Consumer Electronics Speaker Component Project To enhance understanding of the role of the Amoeba model, we present a typical application involving the manufacturing of a custom speaker component. Initially, the project experiences some challenges, including tight tolerance requirements, complex internal acoustic structures, and multi-cavity mold precision. The project employed a coordinated application of different amoebas, including the CNC, mold design, and Rapid Tool Assembly. The application of these Amoebas reduced the mold development cycle by 28%. The team achieved stable dimensional tolerance control. Further, they met deadlines, delivering the ready products to clients on time. This integration of different Amoebas led to a seamless transition from prototype tooling to volume production. Employee Feedback and Annual Meeting Highlights Employees shared different experiences they found with the adoption of the Amoebas. First, they found that using the model made the performance expectations very clear. Others reported a stronger sense of ownership, while others noted better cross-team communication. One noted, "We had problems with problem-solving. Every time a problem arose, we would spend more time discussing and cross-examining policies from different departments. With this model, we have faster problem-solving cycles." Future Plans: Deepening Implementation and Digital Integration First Mold is optimistic that the current model will put it in a stronger competitive position. However, to keep its operations running, the company plans to first refine its internal pricing mechanism. Second, the company plans to enhance its digital migration by introducing digital performance dashboards. Lastly, First Mold aims to strengthen collaboration between mold design and injection process simulation. About First Mold First Mold, a renowned Chinese enterprise engaged in mold manufacturing, plastic injection molding and rapid prototyping, has a 15-year development history. As a modern high-tech manufacturing company, it adopts a dual production base model with facilities in China and Mexico, serving customers in more than 50 countries and regions across the globe. It excels at identifying customers' pain points and understanding their most pressing needs. First Mold's mold products, plastic components and metal rapid prototyping parts have won widespread acclaim all the time. Business Contact:Name: Young LeePosition: Sales ManagerWebsite: https://firstmold.com/E-mail: sales@firstmold.comPhone: +86 13925326660
2026-02-26 09:30:00

한국스트라이커, 8년 연속 '대한민국 일하기 좋은 기업' 선정
소통과 신뢰를 바탕으로 직원의 성장과 삶을 함께 존중하는 근무환경 조성 서울, 대한민국, 2026년 2월 25일 /PRNewswire/ -- 한국스트라이커가 GPTW Institute 주최 '제24회 대한민국 일하기 좋은 기업' 시상식에서 8년 연속 수상하는 영예를 안았다. 또한 '대한민국 여성 워킹맘이 일하기 좋은 기업', '대한민국 밀레니얼이 일하기 좋은 기업' 부문에서도 5년 연속 선정되었으며, 지난해에 이어 '대한민국 부모가 가장 일하기 좋은 기업' 부문에서도 연속 선정되었다. 한국스트라이커는 글로벌 의료기기 기업 스트라이커(Stryker)의 한국 지사로, 정형외과와 신경외과 등 다양한 의료 분야에서 혁신적인 제품과 솔루션을 제공하고 있다. 특히 인공관절 수술 분야에서는 미국 FDA 승인을 받은 로봇 수술 플랫폼 '마코 스마트로보틱스(Mako SmartRoboticsTM)'를 국내에 도입해, 3D CT 기반의 정밀 수술 계획과 로봇 제어 기술을 통해 수술 정확도와 환자 회복의 질을 높이고 있다. 이러한 기술 혁신을 이끄는 기업 철학은 직원과 조직을 바라보는 방식에도 그대로 반영되고 있다. 강점을 기반으로 한 지속 가능한 성장 지원 한국스트라이커는 직원 각자의 강점을 발견하고 업무에 효과적으로 활용할 수 있도록 '강점 진단 검사 및 코칭 프로그램'을 운영하고 있다. Gallup Clifton Strengths 진단을 통해 직원들은 자신의 강점을 이해하고, HR 강점 코치와의 1:1 세션을 통해 개인 맞춤형 성장 방향을 설정한다. 더 나아가 '팀 블렌딩 세션'을 통해 팀 단위의 강점 조합을 점검하고, 개인의 강점이 팀 성과로 확장될 수 있도록 지원하고 있다. 또한 내부 직무 이동 기회를 지속 확대하여 마케팅, 영업, 임상 및 기술 지원 등 다양한 직무 간 경험을 통해 직원들의 커리어 선택권과 성장 가능성을 넓혀가고 있다. 소통과 신뢰를 강화하는 조직 문화 한국스트라이커는 소통과 협력을 조직 운영의 핵심 원칙으로 삼고 있다. 분기별 타운홀 미팅을 통해 회사의 성과와 방향성을 투명하게 공유하고, 직원들이 경영진과 직접 소통할 수 있는 기회를 제공한다. 더불어 상시적인 1:1 대화를 통해 매니저와 직원이 성과뿐만 아니라 성장과 커리어에 대해 지속적으로 논의하는 문화를 정착시켜, 신뢰 기반의 피드백 환경을 강화하고 있다. 자율성과 삶의 균형을 존중하는 근무 환경 한국스트라이커는 자율성과 유연성을 제도적으로 뒷받침하는 근무환경을 운영하고 있다. 주 2~3일 근무 장소를 선택할 수 있는 유연근무제와 탄력적인 출퇴근 제도를 통해 직원들의 업무 몰입도를 높이고 있다. 또한 매월 '패밀리데이', 연말 전사 유급 휴무인 '연말 리프레시 휴식' 제도를 통해 충분한 휴식과 재충전을 지원하고 있다. 이와 함께 골프, 레저, 공연, 재테크, 반려동물, 맛집 모임 등 다양한 동호회 활동과 'Bring Your Children Day'를 운영하며, 직원과 가족을 아우르는 소속감 있는 문화를 만들어가고 있다. 이러한 노력은 직원 개개인의 만족과 성장을 넘어, 조직의 지속 가능한 성과로 이어지고 있다. 한국스트라이커는 앞으로도 소통과 신뢰를 기반으로, 직원과 함께 성장하는 일하기 좋은 기업으로 나아갈 계획이다. 심현우 대표이사는 "스트라이커의 가장 큰 경쟁력은 사람이며, 혁신적인 기술만큼이나 직원들이 신뢰와 성장을 경험할 수 있는 환경을 지속적으로 만들어가는 것이 중요하다"고 밝혔다
2026-02-24 23:00:00

멀츠 에스테틱스 코리아, '가장 일하기 좋은 기업' 2년 연속 1위
서울, 대한민국, 2026년 2월 25일 /PRNewswire/ -- 글로벌 메디컬 에스테틱 리딩 기업 멀츠 에스테틱스 코리아(대표 유수연, 이하 멀츠)가 GPTW '2026 대한민국 가장 일하기 좋은 기업'에서 2년 연속 1위를 달성했다. 이로써 멀츠는 '대한민국 가장 일하기 좋은 100대 기업'에 4년 연속 이름을 올리고, 역대 최초로 2년 연속 1위를 기록하는 쾌거를 이뤘다. 또한, 글로벌 멀츠 에스테틱스는 2025년 GPTW '아시아에서 가장 일하기 좋은 기업' 1위로 선정된 바 있다. 멀츠는 명확한 비전(Visioning)에 대한 구성원들의 공감(Alignment)과 적극적인 참여(Engagement)를 통해, 모든 사람이 더 큰 자신감으로 더 나은 삶을 느끼고 살아가도록 돕는다는 기업 미션을 실현해 가고 있다. 인사 전략으로는 '소속감(Belonging)', '성취감(Performing)', '만족감(Rewarding)'을 중심으로 모든 구성원이 존중 받고 함께 성장할 수 있는 조직 문화를 구축해 왔다. 멀츠는 'Your success is our success'라는 철학 아래, 멀츠만의 스킬 프레임워크를 만들어 직급별 필요한 교육과 스킬 레벨에 대한 가이드를 마련했다. 이에 따라, 직원들은 스스로 역량 개발 및 장기적인 커리어 방향성에 대한 계획을 세우며, 회사는 체계적인 교육 커리큘럼과 외부 교육 및 직무 전환 기회 등을 제공한다. 특히, 2025년부터는 모든 구성원이 각자의 자리에서 심리적 안전감을 바탕으로 공감과 협업을 이끌어 내는 'Authentic Leadership(진정한 리더십)' 문화를 강화하고 있다. 이를 위해 멀츠 스킬 프레임워크와 4Cs(Courage–Connect–Commit–Communicate) 모델을 중심으로 연간 교육 프로그램을 설계하여 직급별로 필요한 리더십 역량을 체계적으로 성장시켜나가고 있다. 이 외에도 '마이 멀츠 익스피리언스 저니(My Merz Experience Journey)' 프로그램을 통해 임직원이 업무 환경 개선, 조직 문화 설계, ESG 캠페인 기획 및 운영 등에 직접 참여하며 일하기 좋은 기업을 만드는 데 일조하고 있다. 아울러, 일과 삶의 균형을 고려한 일하기 좋은 기업을 만들기 위해 다양한 복지 제도도 운영 중이다. ▲유연근무제 ▲월 4회 재택근무 ▲매주 금요일은 오후 4시 퇴근을 장려하는 패밀리데이 등의 근무 체계를 갖추었으며, ▲임산부 및 수유부를 위한 전용 휴게실 ▲자녀 수에 제한 없는 유치원 보조금 지급 ▲초등학교 입학 자녀 돌봄을 위한 3월 추가 재택근무 ▲초등학교 입학 자녀를 위한 입학 선물과 입학식 당일 유급 휴가 등 자녀를 둔 임직원도 일과 가정 모두를 지키며 커리어를 발전시킬 수 있도록 지원하고 있다.
2026-02-24 23:00:00

TheSportExchange Announces Intent to Pursue NASDAQ Direct Listing
Performance-linked digital asset marketplace targeting H2 2026 listing; public launch scheduled for May 1, 2026 NEW YORK, Feb. 25, 2026 /PRNewswire/ -- TheSportExchange ("TSE"), operating as TSE Marketplace Ltd. in Europe, today announced its intent to pursue a direct listing of its ordinary shares on the Nasdaq or New York Stock Exchange. The company is targeting a listing in the second half of 2026, subject to market conditions and regulatory review. Chardan has been retained as financial advisor in connection with the proposed listing. With institutional appetite for sports-linked exposure accelerating, TSE believes now is the right moment to access the capital markets. Building a Performance-Linked Marketplace for Global Sports TSE has developed a digital marketplace enabling participants to acquire and trade performance-linked digital assets ("Keys") tied to professional sports teams and league standings. Asset pricing reflects verified on-field performance data and real-time market demand, creating a structured, transparent framework through which sports performance becomes a continuously tracked, tradable reference — rather than being tied to a binary outcome. Public Launch Scheduled for May 1, 2026 TSE is currently operating in a limited, invite-only phase supporting structured onboarding ahead of full commercial release. The platform is scheduled to launch publicly on May 1, 2026. The launch will introduce World Cup team Keys as the first globally distributed assets on the marketplace. Technology Infrastructure TSE is built on PandaSea Mainnet — a Layer-1 blockchain developed by PandaSea Inc., engineered for high throughput, deterministic settlement, and on-chain transparency across global sports markets. PANDA is the native gas token of PandaSea Mainnet. TSE maintains a treasury of PANDA tokens as part of its operational infrastructure, ensuring liquidity for network settlement and transaction processing. Under PandaSea's network protocol, 0.56% of transaction volume processed on the network is directed toward open-market PANDA repurchases. Further detail regarding TSE's PANDA holdings and its economic relationship with PandaSea Inc. will be set forth in TSE's registration statement. Management Commentary Steve van Zutphen, Founder and CEO of TheSportExchange, stated: "For the first time, sports fans around the world can participate in the performance of the teams they love, on a platform designed to turn fan engagement into new opportunities for the entire sports ecosystem." About TheSportExchange TheSportExchange is a performance-linked digital asset marketplace enabling participants to trade Keys tied to professional sports team performance and league standings, built on PandaSea Mainnet. For more information, visit thesportexchange.com. About PandaSea Inc. PandaSea Inc. is a Delaware-incorporated technology company building institutional-grade blockchain infrastructure. Its PandaSea Mainnet is a Layer-1 Avalanche Subnet, and PANDA is its native gas token. PandaSea's network protocol directs 0.56% of transaction volume toward open-market PANDA repurchases. For more information, visit pandasea.io. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the proposed direct listing, anticipated timing, market expansion, and platform launch. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including market conditions, regulatory developments, blockchain infrastructure risks, competition, and other factors. The company undertakes no obligation to update these statements except as required by applicable law. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any such offer will be made only by means of a prospectus filed with and declared effective by the Securities and Exchange Commission.
2026-02-24 23:00:00

허먼밀러, ESD 업무 환경을 위한 '에어론 ESD 체어' 출시
서울, 대한민국, 2026년 2월 25일 /PRNewswire/ -- 글로벌 프리미엄 가구 브랜드 허먼밀러가 지난 2월 11일-13일, SEMICON Korea에서 ESD 민감 작업 환경을 위한 에어론 ESD 체어 및 스툴을 선보이며, 한국 반도체/전자/첨단 제조 산업 시장 공략을 본격화했다. 이번 제품 라인은 ESD 관리가 요구되는 환경에서도 사람들이 편안하게 일할 수 있도록 설계되었으며, 글로벌 ESD 기준과 에어론 체어의 인체공학적 퍼포먼스를 함께 담아냈다. ESD 민감 환경을 위한 시팅 솔루션 에어론 ESD는 반도체 및 첨단 기술 산업의 클린룸, 데이터 센터, 실험실, 전자 제품 조립 구역 등 ESD 민감 환경에서 일하는 사람들을 위해 설계되었다. 허먼밀러는 ESD 작업 공간에서는 의자와 같은 가구가 정전기 방전의 주요 원인이 될 수 있다는 점에 주목해, 기존 에어론 체어의 착좌감과 지지력을 유지하면서 ESD 기능을 동시에 제공하는 솔루션을 개발했다. 에어론의 인체 공학 퍼포먼스를 ESD 업무 환경으로 허먼밀러 에어론 체어는 빌 스텀프와 돈 채드윅이 1994년 선보인 이후, 지속적으로 소재와 디자인을 발전시키며 인체공학적 오피스 체어의 기준을 제시해왔다. 에어론 ESD는 이러한 에어론 고유의 인체공학적 퍼포먼스를 기반으로, ESD 업무 환경에서 일하는 사람들을 위해 설계되었다. 8Z 펠리클 서스펜션은 체중을 균형 있게 분산시켜 장시간 앉아있어도 압박을 줄이고, 통기성을 통해 열 축적을 최소화한다. 조절 가능한 PostureFit SL은 척추 하부를 안정적으로 지지하며, Harmonic 2 Tilt는 자연스럽고 균형 잡힌 리클라인을 제공한다. 대부분의 ESD 의자가 단일 사이즈로 제공되는 것과 달리, 허먼밀러는 두 가지 체어 사이즈와 두 가지 실린더 높이 옵션을 제공함으로써 사용자의 체형과 작업 환경에 보다 정밀하게 대응한다. 등받이 높이, 시트 폭, 틸트 메커니즘, 그리고 베이스 크기 면에서 보다 사용자에게 맞는 의자를 선택할 수 있다. 지속가능성을 고려한 솔루션 기존 ESD 의자가 주로 폼, 패브릭, 가죽 중심으로 제작되어 온 것과 달리, 에어론 ESD는 기능성과 함께 지속가능성을 핵심 가치로 삼는다. 제품의 50% 이상이 재활용 소재로 구성되었으며, 일부 부품에는 해양 유입 폐플라스틱(ocean-bound plastic)이 사용되었다. 이는 허먼밀러가 오랜 시간 이어온 지속가능성에 대한 약속을 반영한다. 글로벌 공급 확대 허먼밀러는 지난 2월 11-13일 개최된 SEMICON Korea에서 에어론 ESD 체어 및 스툴을 선보이며, 방문객들이 직접 제품을 체험할 수 있는 공간을 운영했다. 해당 제품은 한국을 포함한 글로벌 시장에서 만나볼 수 있으며, 제품에 대한 자세한 사항은 전 세계 밀러놀 공식 딜러를 통해 문의 가능하다. 이미지 더 보기 허먼밀러(Herman Miller) 소개 지난 한 세기동안 허먼밀러는 사람들에게 영감을 주는 문제 해결 중심의 디자인에 대한 신념 아래 성장해왔다. 그 여정 속에서 허먼밀러는 당대 가장 혁신적인 디자이너들과 긴밀한 협업을 이어왔다. 조지 넬슨(George Nelson)과 임스 오피스(Eames Office), 이사무 노구치(Isamu Noguchi)와 같은 미드센추리 거장부터, 연구 중심의 비전을 제시한 로버트 프로스트(Robert Propst)와 빌 스텀프(Bill Stumpf), 그리고 오늘날 새로운 가능성을 제시하는 인더스트리얼 파실리티(Industrial Facility)와 스튜디오7.5(Studio 7.5)에 이르기까지 폭넓은 파트너십을 구축해왔다. 인체공학 가구의 탄생을 이끌고, 20세기를 대표하는 아이코닉한 디자인을 선보여온 허먼밀러는 시대를 초월하는 오리지널 디자인을 통해 지속적인 영향을 만들어오고 있으며, 동시에 디자인, 혁신, 그리고 사회적 가치를 아우르는 유산을 쌓아왔다. 허먼밀러는 우리가 살아가는 세상을 디자인하기 위해 모인 브랜드 컬렉티브 MillerKnoll의 일원이다. 허먼밀러에 대한 더 자세한 정보는 hermanmiller.com/about에서 확인할 수 있다.
2026-02-24 23:00:00

한국리미니스트리트, 협업 혁신으로 '일하기 좋은 기업' 위상 강화
한국리미니스트리트, 하이브리드 협업 혁신으로 '일하기 좋은 기업' 위상 강화 서울, 대한민국, 2026년 2월 25일 /PRNewswire/ -- 글로벌 엔터프라이즈 소프트웨어 지원 분야를 선도하는 리미니스트리트(Rimini Street Inc.)가 대한민국에서 '일하기 좋은 기업'으로 선정되며, 사람 중심 경영과 지속적인 업무 혁신의 성과를 다시 한번 입증했다. 특히 한국리미니스트리트는 하이브리드 근무 환경을 기반으로 한 협업 인프라 고도화와 직원 경험을 핵심 경쟁력으로 삼아, 일과 성과, 그리고 조직 문화를 동시에 성장시키는 기업으로 주목받고 있다. 리미니스트리트는 '탁월한 인재들이 만들어내는 차별화된 기술 솔루션extraordinary technology solutions powered by extraordinary people'라는 사람 중심의 브랜드 철학 아래, 전 세계 고객을 대상으로 24/7/365 글로벌 지원 체계를 운영하고 있다. 평균 15년 이상의 경력을 보유한 소프트웨어 전문가들이 제공하는 고품질 서비스는 고객 만족도 4.9/5.0이라는 수치로 이어지며, 글로벌 시장에서 독보적인 신뢰를 쌓아왔다. 이러한 성과의 기반에는 기술력뿐만 아니라, 구성원 개개인의 전문성과 몰입도를 극대화하는 조직 문화가 자리하고 있다. 한국리미니스트리트가 특히 높은 평가를 받은 요소는 직원 경험을 중심에 둔 하이브리드 협업 환경이다. 회사는 단순히 재택근무와 출근을 병행하는 수준을 넘어, 어디에서 일하든 동일한 생산성과 협업 품질을 유지할 수 있도록 업무 환경 전반을 재설계했다. 구성원들은 업무 특성과 개인의 라이프스타일에 맞춰 사무실과 재택근무를 유연하게 오가며, 자율성과 책임을 기반으로 한 근무 문화를 실현하고 있다. 2025년 확장 이전을 완료한 한국 오피스는 이러한 철학을 공간으로 구현한 대표적인 사례다. 기존 대비 책상 폭을 1,200mm에서 1,700mm로 확대해 개인 업무 집중도를 높였으며, 대형 회의실과 라운지, 협업을 위한 크리에이티브 공간을 대폭 확충했다. 단순한 업무 공간을 넘어 '일하고 싶은 공간'으로 설계된 오피스는 구성원 간 자연스러운 소통과 아이디어 교류를 촉진하며, 하이브리드 환경에서도 팀워크를 강화하는 역할을 하고 있다. 업무 운영 측면에서도 디지털 전환을 통한 효율화가 눈에 띈다. 통합 협업 플랫폼과 핵심 업무 시스템을 중심으로 한 디지털 인프라를 구축해, 전 세계 동료들과의 연결성을 높이고 업무 프로세스 자동화를 구현했다. 이를 통해 업무 투명성과 문제 해결 속도를 크게 향상시켰으며, 보다 일관되고 효율적인 글로벌 협업 체계를 마련했다. 또한 모든 구성원에게 최신 IT 보안 환경이 적용된 개인 노트북을 지급해, 언제 어디서나 동일한 수준의 업무 환경과 고객 서비스 품질을 유지할 수 있도록 지원하고 있다. 이러한 변화의 중심에는 '신뢰'에 기반한 리더십 철학이 있다. 김형욱 한국리미니스트리트 지사장은 다음과 같이 말했다. "리미니스트리트의 하이브리드 근무 문화는 단순한 제도가 아니라, 사람을 신뢰하는 조직 문화에서 출발합니다. 우리는 직원들이 언제, 어디서 일하는가보다 어떤 가치를 만들어내는가를 더 중요하게 생각합니다. 회사가 먼저 신뢰를 보내면, 직원들은 그에 대한 책임과 성과로 답한다고 믿고 있습니다." 하이브리드 근무 환경에서도 조직의 결속력은 오히려 더욱 강화되고 있다. 지역별 소모임, 버디(Buddy) 프로그램, 글로벌 웰빙 활동, 온•오프라인을 결합한 팀 빌딩 등 다양한 참여 프로그램을 통해 'Rimini Family' 문화가 촘촘히 유지된다. 특히 한국팀의 모든 구성원이 "자신의 업무가 의미 있고 자부심을 느낀다"고 응답한 점은, 이러한 신뢰 기반 문화가 현장에서 실질적으로 작동하고 있음을 보여준다. 김형욱 지사장은 이어 "앞으로도 직원들이 스스로 성장하고 도전할 수 있는 환경을 만드는 데 지속적으로 투자할 것"이라며, "이를 통해 직원과 고객 모두에게 더 나은 경험을 제공하는 것이 한국리미니스트리트의 궁극적인 목표"라고 덧붙였다. 한국리미니스트리트는 향후에도 하이브리드 근무 환경과 디지털 협업 역량을 지속적으로 고도화하며, 대한민국을 대표하는 '일하기 좋은 기업'의 표준을 만들어갈 계획이다.
2026-02-24 23:00:00

TheSportExchange宣布计划在纳斯达克直接上市
表现关联数字资产市场目标于2026年下半年上市;计划于2026年5月1日公开上线 纽约2026年2月25日 /美通社/ -- TheSportExchange(简称“TSE”),在欧洲以TSE Marketplace Ltd.名义运营,今日宣布其计划在纳斯达克或纽约证券交易所直接上市其普通股。 该公司的目标是在2026年下半年上市,具体取决于市场状况和监管审查。 Chardan已受聘担任本次拟议上市的财务顾问。 随着机构对体育关联敞口的兴趣加速增长,TSE认为现在是进入资本市场的恰当时机。 为全球体育行业打造表现关联市场 TSE开发了一个数字市场,使参与者能够获取和交易与职业体育球队及联赛排名挂钩的表现关联数字资产(“Keys”)。 资产定价反映经验证的赛场表现数据和实时市场需求,从而构建一个结构化、透明的框架,使体育表现成为可持续追踪、可交易的价值参考,而非仅仅与单一的二元结果挂钩。 计划于2026年5月1日公开上线 TSE目前正处于有限的邀请制试运行阶段,在全面商业发布前支持结构化用户入驻。 该平台计划于2026年5月1日公开上线。 上线时,平台将率先推出世界杯球队Keys,作为其面向全球发行的首批资产。 技术基础设施 TSE基于PandaSea主网构建,该主网由PandaSea Inc.开发,是一条Layer-1区块链,专为在全球体育市场中实现高通量、确定性结算及链上透明度而设计。 PANDA是PandaSea主网的原生Gas代币。 TSE持有PANDA代币作为其运营基础设施的一部分,以确保网络结算和交易处理的流动性。 根据PandaSea网络协议,在其上处理的交易量中,将有0.56%用于从公开市场回购PANDA代币。 关于TSE持有的PANDA资产及其与PandaSea Inc.经济关系的更多细节,将在TSE的注册声明中予以披露。 管理层评论 TheSportExchange创始人兼首席执行官Steve van Zutphen表示: “全球体育迷将首次能够参与到自己所热爱球队的表现之中,并通过一个旨在将球迷参与转化为整个体育生态系统新机遇的平台实现这一点。” 关于TheSportExchange TheSportExchange是一个表现关联型数字资产市场,使参与者能够交易与职业体育球队表现及联赛排名挂钩的Keys,该平台基于PandaSea主网构建。 如需了解更多信息,请访问thesportexchange.com。 关于PandaSea Inc. PandaSea Inc.是一家在特拉华州注册成立的技术公司,致力于建设机构级区块链基础设施。 其PandaSea主网是一个Layer-1 Avalanche子网,PANDA是其原生Gas代币。 PandaSea网络协议将0.56%的交易量用于从公开市场回购PANDA代币。 如需了解更多信息,请访问pandasea.io。 关于前瞻性陈述的警示性声明 本新闻稿包含前瞻性陈述,包括关于拟议直接上市、预期时间、市场扩张和平台发布的陈述。 这些陈述受风险和不确定性的影响,可能导致实际结果存在实质性差异,包括市场条件、监管发展、区块链基础设施风险、竞争和其他因素。 公司没有义务更新这些陈述,适用法律要求除外。 本新闻稿不构成出售要约或证券购买要约。 任何此类要约将仅通过向美国证券交易委员会提交并宣布生效的招股说明书进行。
2026-02-24 23:00:00

애터미, 6년 연속 '대한민국에서 가장 일하기 좋은 기업'
아기철학으로 애터미의 기업문화...영혼을 소중히 여긴다 서울, 대한민국, 2026년 2월 25일 /PRNewswire/ -- 애터미가 6년 연속 '대한민국에서 가장 일하기 좋은 기업 (2026년 2위)' 및 '글로벌 ESG 인권 경영 인증', '부모가 일하기 좋은 기업'에 선정되며 3관왕에 올랐다. 애터미는 '영혼을 소중히 여긴다'는 사훈 아래 임직원들의 자유롭고 진취적인 업무환경을 갖춰놓았다. 사람은 '수단'이 아닌 '목적' 그 자체라고 말하는 애터미 박한길 회장. 이러한 핵심가치를 경영에 녹여내어 대한민국 일하기 좋은 기업(GPTW)을 만들었으며, 6년 연속 한국에서 가장 존경받는 CEO에 선정되었다. [박한길/20190605/공주/박종근] 박한길 (주)애터미 회장/대표이사/포브스 코리아 인터뷰/ 영혼을 소중히 - 직원은 그 자체로 이미 기업의 목적 애터미의 임직원 사랑은 유별나다. '영혼을 소중히 여긴다'는 사훈에서도 알 수 있듯이 임직원은 단순히 애터미의 구성요소가 아니라 함께 성장하고 발전해야 할 존재다. 박한길 애터미 회장"사람은 어떤 경우에도 수단이 될 수 없다. 그 자체로 목적이기 때문이다. 당연히 애터미 임직원도 그 자체로 애터미의 목적이지 성장의 도구가 되어서는 안된다"고 말했다. 애터미에서 말하는 '젖소철학 아기철학'이 이를 대변한다. '젖소를 소중히 여기는 목장 주인은 젖소가 가져다 준 수익 때문이지만 아기를 소중히 여기는 어머니는 아기가 가져다 줄 이익이 아니라 아가 그 자체가 사랑스럽고 소중 하기 때문'이라는 것이다. 실제로 애터미 직원들은 충만한 자신감으로 일하고 있다. 애터미의 일하는 정신의 첫 번째에는 '후츠파'가 있기 때문이다. 상사의 말이라도 아니다 싶으면 상사가 설득되든지 본인이 설득되든지 끝까지 도전한다. 이것이 바로 형식과 권위에 얽매이지 않고 자신의 주장을 당당히 밝히는 후츠파 정신이다. 이를 가능케 하는 것이 바로 수평적인 조직문화다. 사람 아래 사람 없고 사람 위에 사람 없다. 모든 영혼은 똑같이 소중하기 때문이다. 애터미의 사옥인 '애터미파크'도 영혼을 소중히 여기는 애터미의 실상과 일 하는 방식을 제대로 보여주고 있다. 사옥 곳곳에는 미끄럼틀이나 그네, 안마의자, 트램펄린, 미니어처 농구장, 탁구대, 수영장, 체육관 등등 쉬거나 놀 수 있는 공간들이 배치되어 있다. 실제로 애터미 파크는 개인 업무공간보다 공용공간이 훨씬 넓다. 박한길 회장은 곧잘 직원들에게 놀다가 지치면 일하라고 말한다. 업무가 스트레스의 주범이 아니라 자기 성장의 도구가 되는 곳, 직원들이 자유로운 공간에서 창의적인 아이디어를 생산하는 곳, 바로 애터미다. 애터미 박한길 회장은 한국에서 가장 존경받는 CEO에 대한민국 최초 6년 연속 선정되었으며, 일하기 좋은 기업을 만들기 위해 리더십을 발휘한 임원에게 주는 GPTW 파이오니아상은 이현우 전무에게 돌아갔다. 한편 박귀용 실장 (CVI:Customer Value Innovation팀)은 대한민국 GPTW혁신리더에, 김희연 팀장(Business Support팀)은 자랑스러운 워킹맘에 각각 선정됐다.
2026-02-24 23:00:00

Big Tree Cloud Secures First Batch of AI-Enabled Enterprise Platform Development Contracts
SHENZHEN, China, Feb. 23, 2026 /PRNewswire/ -- Big Tree Cloud Holdings Limited (the "Company") (NASDAQ: DSY) today announced that its AI business has made initial progress in technology development and services for enterprise clients (B2B), having signed its initial technical service agreements with a total contract value of approximately RMB 4.5 million (approximately US$620,000). This marks a key step in the Company's strategic deployment in the AI commercial application sector. Leveraging deep insights into industry needs and technological integration capabilities, the Company, through its operating entity, has partnered with multiple enterprise clients and signed technical service agreements. The agreements include providing comprehensive technology development for an AI-centric platform for a strategic partner, as well as for a third-party client in the education sector. These contracts encompass long-term framework collaborations, customized project development, and ongoing maintenance services. Such partnerships reflect market interest in the Company's enterprise-focused platforms that integrate AI-powered functionalities. The Company provides enterprise-level platform development and system integration, including front-end and back-end development, architecture set up, system delivery, and other long-term, end-to-end services that effectively support businesses in achieving digital transformation and strategic implementation. While these initial contracts are with enterprise clients (B2B), the platforms under development are designed to serve individual end-users (B2C). One of the platforms being developed is an AI learning and application platform intended to cultivate "AI application-oriented talent" for university students and young professionals. This strategy of empowering B2B clients who serve B2C users allows the Company to indirectly tap into the individual user market, laying a foundation for potential synergies between its enterprise services and the broader consumer technology ecosystem. Management Commentary Mr. Wenquan Zhu, Chairman of the Board of the Company, stated, "We will continue to invest in both enterprise and individual AI businesses, providing actionable solutions for enterprises through professional teams and building efficient learning systems for individual users to achieve sustainable growth." Ms. Xiaoxuan Zhu, Director and Co-Chief Executive Officer, added, "We are committed to building an AI platform that connects talent development with corporate needs. By developing platforms that bridge corporate needs with talent development and deepening the synergy between B2B and B2C segments, we aim to create long-term value for all stakeholders." About Big Tree Cloud Founded in 2020, Big Tree Cloud is positioned as an international capital platform focused on industrial integration and strategic investment in China's personal care industry. The Company is committed to empowering industries through capital operations. Currently, Big Tree Cloud is accelerating its expansion into the AI sector. This new business line aims to capture the growing market demand for AI skills, injecting fresh momentum into the Company's development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. These statements involve risks and uncertainties and relate to, among other things, the Company's future business development, growth strategies, and operational plans. These forward-looking statements include, but are not limited to, the Company's ability to successfully develop and commercialize the AI platforms for its clients, the market acceptance of these platforms by end-users, the potential synergies between B2B and B2C businesses, and the Company's ability to achieve sustainable growth. Actual results may differ materially from those expressed or implied in such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the evolving regulatory environment in China, competition in the AI industry, the Company's ability to retain key personnel and technology, and other risks detailed in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law. Investor Relations ContactTing YanPhone: +86 15986815865Email: yanting@bigtreeclouds.com
2026-02-23 13:00:00

iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the company's "AI + Chemical Induction" platform saw its first U.S. patient dosed for Parkinson's disease at Weill Cornell Medical Center and its first patient enrolled for Multiple System Atrophy (MSA) at Beijing Tiantan Hospital. These parallel milestones for NouvNeu001 and NouvNeu004 represent the next phase of iRegene's global strategy, transitioning from early safety data into mid-stage clinical trials designed to rigorously evaluate therapeutic efficacy across international patient cohorts. First Patient Dosed in U.S. Phase IIa Trial of NouvNeu001 for Parkinson's Disease NouvNeu001 is an investigational off-the-shelf cell therapy derived from induced pluripotent stem cells (iPSCs) and chemically induced into dopaminergic progenitor cells. The therapy was administered via stereotactic neurosurgery into the bilateral putamen at Weill Cornell Medical Center in the first patient of an open-label U.S. Phase II study. Building on positive Phase I data, the U.S. Food and Drug Administration (FDA) cleared NouvNeu001 for direct Phase II entry in the Q3 2025, following Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation. This progression validates iRegene's preclinical and clinical package and robust CMC framework, enabling closer FDA collaboration and accelerated pathways. NouvNeu001 is designed to address the underlying pathology of Parkinson's disease by replacing lost dopaminergic neurons and modifying disease progression — a "single dose, sustained benefit" approach aimed at addressing critical unmet needs. With the first patient dosed in U.S., parallel Phase II trials continue in both the U.S. and China. First Patient Enrolled in China for MSA Trial with NouvNeu004 In parallel, iRegene has enrolled the first patient in a randomized controlled clinical trial in China evaluating NouvNeu004, its allogeneic iPSC-derived off-the-shelf cell therapy candidate for Multiple System Atrophy (MSA). Led by Principal Investigator Professor Yilong Wang at Beijing Tiantan Hospital, Capital Medical University, the study marks a significant advancement for MSA – a rapidly progressive neurodegenerative disorder with no approved disease-modifying therapies. NouvNeu004 employs a dual "neurotrophic support + neural reconstruction" strategy, providing trophic support to affected brain regions while promoting functional neural differentiation to potentially halt or reverse progression. China's NMPA approved the integrated Phases I–III trial application in October 2025, while the U.S. FDA has granted a special exemption and cleared an international Phase I trial, enabling efficient simultaneous development in both countries. "Dosing the first U.S. patient for Parkinson's disease and enrolling the first MSA patient in China are pivotal milestones in our mission to deliver transformative, disease-modifying therapies to patients worldwide," said Dr. Meng Cai, Chief Medical Officer of iRegene Therapeutics. "These parallel advances reflect the productivity of our 'AI + Chemical Induction' platform, yielding two pioneering 'off-the-shelf' cell therapies: NouvNeu001 for Parkinson's disease and NouvNeu004 for Multiple System Atrophy. Together, they demonstrate our commitment to a robust global development pathway and our continued contribution to the advancement of cell therapy for neurodegenerative diseases." The "AI + Chemical Induction" Advantage: From Proof-of-Concept to Industrial Validation iRegene's core strategy centers on its proprietary "AI + Chemical Induction" platform, engineered to bring scalability and consistency to cell therapy manufacturing. While traditional differentiation methods frequently rely on complex growth factors and commercial media cocktails – which are often prone to batch-to-batch variability and high costs – iRegene utilizes algorithm-optimized small molecule combinations to direct cellular differentiation toward specific lineages. This chemical induction approach is designed to reduce batch-to-batch variability and support consistent manufacturing under a stable CMC framework, facilitating true off-the-shelf production at lower costs with reduced supply chain complexity compared to personalized or growth factor-dependent therapies. The platform's foundational technology has been granted patents across China, Japan, and the U.S. Building on this foundation, iRegene is developing a pipeline of universal, iPSC-derived cell therapies for currently incurable diseases, led by its flagship program and several novel candidates: NouvNeu001 for Parkinson's disease – The world's first clinical-stage, allogeneic iPSC-derived, chemically induced dopaminergic progenitor cell therapy for PD; holds dual FDA FTD (August 2025) and RMAT (December 2025) designations; IND cleared in both China and the U.S.; now in Phase II trials in both China and the U.S. NouvNeu003 for early-onset Parkinson's disease – The company's second product candidate. IND approved by China's NMPA (December 2023); Phase I completed in China. NouvNeu004 for Multiple System Atrophy – World's first "AI + Chemical Induction"-derived cell therapy to enter clinical development for MSA; IND approved by China NMPA covering Phases I–III; U.S. FDA special exemption and international Phase cleared; first patient enrolled in China randomized trial. NouvSight001 for Retinal Degenerative Diseases (RDDs) – U.S. FDA Orphan Drug Designation granted (March 2024); advancing as an innovative ophthalmology therapy. This expanding pipeline underscores the versatility of iRegene's underlying technology, demonstrating the platform's capacity to deliver a new generation of scalable cell therapies for complex neurodegenerative disorders. As these candidates move into advanced clinical stages, they represent a tangible shift toward establishing chemically induced iPSC-derived treatments as a safe and effective pillar of global regenerative medicine. About iRegene Therapeutics Founded in 2017 by a team of international professionals, iRegene Therapeutics is a pioneer in applying "Chemical Induction" to precisely reprogram cell fate and optimize cellular functions for innovative cell therapies. Leveraging its proprietary "AI + Chemical Induction" platform, iRegene has built a robust pipeline targeting currently incurable diseases, including Parkinson's disease and Multiple System Atrophy.
2026-02-23 13:00:00

Daily Associated News: DAVOLINK Transforms from Wireless Network Equipment Supplier to AI-Based Robotics Integrated Control Platform Company
- Merging AI robot control and wireless networks... Presenting an impactful vision enabling short- and long-term revenue growth by evolving beyond a simple network equipment supplier into an integrated robot automation control design company - A strategic move to restore shareholder trust, preempt future industrial markets, and compete through technology convergence ANYANG, South Korea, Feb. 23, 2026 /PRNewswire/ -- DAVOLINK, a network security and solutions specialist, is strategically merging with LoadRunner, a smart factory solutions provider. This move signals its transition beyond being a simple security Wi-Fi equipment supplier to becoming an intelligent communications and security integrated platform company. Following its recent announcement of plans to strengthen financial soundness, expand transparent IR, and implement shareholder-friendly policies, DAVOLINK has positioned the technological merger with LoadRunner—beyond an MOU—as a core pillar for future growth. DAVOLINK's intent to embrace LoadRunner extends beyond simple cooperation or a robotics technology partnership. LoadRunner possesses a platform and automation robot technology featuring large-scale data processing, AI-based analysis, and automated workflow design capabilities, excelling in real-time event processing and building integrated control environments. It is already expanding business revenue in industrial settings. It is not merely a company presenting a future robotics vision. This distinct advantage is why DAVOLINK chose to pursue integration with LoadRunner at this critical juncture. By combining DAVOLINK's expertise in wireless network design, construction, and operation with LoadRunner's AI analysis engine and robot integration design, DAVOLINK can expand its architecture to simultaneously encompass network infrastructure and data intelligence. The core of this merger strategy is 'Intelligent Integrated Control'. While existing network security environments focused on rule-based detection and post-incident response, applying LoadRunner's AI analysis system and robot technology enables real-time traffic anomaly detection, threat prediction, and automated response processes. The vast log, traffic, and terminal data collected at the wireless network edge, linked with the central analysis engine, creates a structure where ultra-low-latency analysis and immediate blocking systems operate simultaneously, making it immediately applicable to industrial sites. DAVOLINK's wireless network technology already demonstrates competitive strength in enterprise-grade RF design, large-scale endpoint connectivity, edge computing integration, and high-speed traffic management. When combined with LoadRunner's AI-powered analytics and robotics-integrated control systems, the network itself evolves beyond simple connectivity into an intelligent decision-making system. This can extend beyond security threat detection to include network optimization, automatic traffic distribution, and predictive failure management. The convergence of telecommunications infrastructure and AI-based integrated control systems carries significant structural implications for future industrial markets. Industries such as manufacturing, logistics, smart factories, smart cities, defense, and robotics automation generate massive real-time data from IoT sensors, edge devices, and autonomous systems. These sectors require not just connectivity, but intelligent networks capable of analyzing and orchestrating operations in real time. DAVOLINK and LoadRunner's integrated strategy reflects this demand. By combining telecommunications, AI, security, robotics, and integrated control design, the partnership targets both near-term revenue opportunities and long-term platform value creation. This represents more than a technological upgrade. It is a redefinition of the business model. Rather than remaining focused on hardware sales, DAVOLINK intends to transition toward a platform-as-a-service structure. Following initial network deployment, recurring revenue can be generated through ongoing monitoring services, data analytics subscriptions, and robotics-integrated control system operations. From an investor perspective, this shift introduces both short-term performance potential and long-term platform scalability as key valuation drivers. A DAVOLINK executive described the phased integration strategy with LoadRunner as a strategic inflection point that goes beyond technical cooperation to secure global competitiveness for both companies. Market analysts interpret this as an effort to restore shareholder confidence while presenting a clearly defined growth roadmap. The combination of financial stabilization initiatives and platform expansion strategy reflects a dual-track approach aimed at operational restructuring and future market leadership. Ultimately, the integration signals DAVOLINK's evolution from a network infrastructure company into an AI-driven intelligent security and robotics-integrated control platform provider. As network infrastructure and data intelligence converge, DAVOLINK may position itself as a core infrastructure player within the future robotics and automation ecosystem. Industry experts suggest this strategic move represents a structural transformation designed to secure differentiated global competitiveness through technological convergence. The company acknowledges investor concerns and has stated its intention to restore trust through transparent execution while simultaneously reshaping its long-term industrial positioning. By expanding telecommunications capabilities into robotics automation design and integrated control systems, DAVOLINK is presenting what it describes as a realistic, high-impact future technology vision capable of generating both short-term and long-term revenue streams. With the LoadRunner MOU, DAVOLINK has signaled renewed strategic momentum. Robotics industry analysts view the partnership as symbolically and structurally significant, marking the company's entry into intelligent robotics-integrated control system design and operations.
2026-02-23 13:00:00

Ramco Systems 推出 Chia,以企業級對話式人工智能代理提升客戶體驗
印度清奈2026年2月19日 /美通社/ -- 全球企業軟件公司 Ramco Systems 今日宣佈推出 Chia,正式進軍代理式人工智能 (AI) 產品領域,務求以這款對話式人工智能代理平台徹底改變企業與客戶的溝通模式。 Chia 專為企業而設,能夠穩定地自動化處理各項複雜的客戶支援互動,減少人手干預、加快回應速度,同時降低營運成本,協助企業大規模締造優質客戶體驗。 Chia helps enterprises automate complex customer support interactions with reliability and scale, reducing manual effort and response times while improving overall customer experience. Chia 是 Ramco 全新人工智能驅動任務自動化套件 rTask 的一部分,其所提供的企業級對話式代理不止於回答問題,更能自主推理、決策和行動,在企業各個系統之間執行端對端工作流程。 藉此平台,企業得以從「人機協作」的支援模式,邁向「僅在例外情況才要人手介入」的未來,將繁重工作交給人工智能處理。 Chia 能執行多步驟後端操作以圓滿解決客戶訴求,過程中與企業系統無縫對接,一切行動亦嚴守既定目標、合規要求及安全準則。 Chia 的核心是其無代碼人工智能代理開發平台。客戶體驗 (CX) 團隊只要使用簡單英文指令,就能自行設計、設定和部署人工智能代理,從此告別漫長工程開發週期。 透過自然語言工作流程 (NLW) 功能,非工程團隊也能用簡單英文定義人工智能邏輯,例如設定退款資格、預訂驗證或政策執行規則。 系統會將這些規則轉化為具確定性的人工智能行動,有效防止產生幻覺。 機構只需數週即可部署首個人工智能代理,大幅縮短實現價值的時間。 Chia 的主要功能包括: 某些行業均可受惠於 Chia,包括: 自然語言工作流程建構工具:以簡單英文設計和更新人工智能邏輯 多步驟工作流程編排:統一管理及編排多個專用人工智能代理,協同處理複雜的多步驟工作流程 全方位渠道對話能力:可於電郵、即時對話及通訊平台與用戶互動 實時系統整合:安全地即時連接企業系統(包括 CRM、ERP、ITSM、HRIS)以執行各項任務 企業知識搜尋:從可靠內容中提取資料,提供有理有據的準確答案 多語言及多模態:支援多種語言的文字及視覺輸入,語音功能快將推出 人工介入升級:需要時可將個案及所有相關資料以流暢無縫方式轉交真人支援團隊跟進 企業級安全與私隱:配備基於角色的存取權限、數據加密、審計日誌及內置合規管控,保障敏感資料安全 可解釋性及工作流程日誌:提供人工智能行動的完整透明度,讓合規報告、審計及根本原因分析工作變得一目瞭然、輕鬆掌握 表現控制面板:可追蹤攔截率、客戶滿意度 (CSAT)、問題解決率及知識缺口,並分析客戶真實意圖,從而持續加強支援成效。 電子商務:將訂單、退貨、退款及銷售流程自動化,即使在交易高峰期,仍能貫徹一致地更快解決客戶問題 旅遊與款待業:旅遊旺季期間,跨平台簡化預訂、更改行程、取消預訂及客戶支援等流程 科技及軟件即服務 (SaaS):將客戶入門、技術支援及帳戶管理流程自動化,並在整個客戶生命週期內提供切合語境的準確回應 金融服務:在符合企業級安全標準、準確規定及監管要求的前提下,從容應對海量查詢 健康與保健:自動化預約排程、後續跟進及健康支援,以同理心為本,嚴守合規底線與客戶互動 媒體與娛樂:於流量高峰期間,大規模處理訂閱、內容探索及客戶支援 通訊與電訊:自動化處理客戶服務、帳單查詢及技術支援,確保體驗始終如一,同時又能即時回應。 Ramco Systems 董事總經理 Abinav Raja 稱:「全球市場對人工智能系統的需求正急速增長,大家渴求的不再只是單純的對話機械人,而是真正具備自主代理能力、能獨立推理、採取行動並交付可衡量成果的系統,而 Chia 正好呼應時代需求。 Chia 是我們首個人工智能原生產品,標誌著 Ramco 轉型過程的重要里程碑。 這只是我們宏大藍圖的序幕,未來將有源源不絕的人工智能原生創新,貫穿整個產品體系。 是次發佈與公司願景一脈相承,也就是將整個平台徹底轉型為人工智能原生,把代理智能注入我們建立的每件產品。 我們相信企業軟件的未來必將以代理智能為核心,具備自主、自行適應和持續演變的能力。Ramco 矢志投入,引領變革。」 Ramco Systems 總裁兼營運總監 Sandesh Bilagi 指出:「現今客戶對服務要求甚高,期望在每個接觸點都能獲享準確快速、流暢無縫的支援。 Chia 迎接挑戰,讓企業運籌帷幄,自信十足地將複雜的客戶互動自動化。 憑著 Chia,團隊僅需數週而非數月即可部署就緒的生產級人工智能代理。企業得以擺脫冗長的實施週期,實現支援體系現代化,最終為客戶締造更迅捷、更一致的體驗。」 關於 Ramco Systems: Ramco Systems 是世界一流的企業軟件產品/平台供應商,憑藉其多租戶雲端技術及流動企業軟件方案,成功顛覆市場,引領創新超過 25 載。 多年來,Ramco 屢創佳績,持續為全球超過 800 間企業、逾 200 萬用戶提供服務,在環球薪酬管理、航空、航天與國防,以及企業資源規劃 (ERP) 等領域,創造出有目共睹的業務成果。 Ramco 的關鍵優勢,在於其革命性的企業應用組裝及交付平台,這正是我們創新產品開發方法的核心。 在創新最前線,Ramco 積極運用人工智能、機器學習、機械人流程自動化 (RPA) 及區塊鏈等先進科技,以助企業實踐數碼轉型。 如欲了解更多資料,請瀏覽 https://www.ramco.com/ai/conversational-ai 在 LinkedIn 關注 Ramco,並緊貼 https://www.ramco.com/ai/conversational-ai/blog 動向
2026-02-19 07:18:00

Space crew rings in Year of the Horse
They are 400km above Earth and cannot go home for the Spring Festival this year, but China's taikonauts have found their own ways to make the traditional Chinese holiday warm and sweet.The Shenzhou-21 crew aboard the space station Tiangong, which means Heavenly Palace, are celebrating the upcoming Chinese Lunar New Year, the Year of the Horse. On Monday, Chinese New Year's Eve, the three taikonauts sent their greetings to Earth via a video released by the China Manned Space Agency."I wish everyone all the best and peace," said commander Zhang Lu.This is the second time he has spent the festival in space. Zhang also took part in the Shenzhou-15 mission, launched in November 2022, and stayed in orbit for six months back then.For taikonaut Wu Fei, this is his first Spring Festival in orbit, an experience he described as fresh and proud. "The Year of the Horse calls for the vigour of a galloping steed. Let us keep striving for our dreams and working for happiness," the young flight engineer said. "I wish you a safe and smooth journey ahead, and a life that gets better and better." It is also the first time payload specialist Zhang Hongzhang has rung in Chinese New Year in space. Noting that scientific experiments on the space station are progressing steadily, the bespectacled, poetry-loving taikonaut said: "In the new year, we will continue to explore the cosmos like a galloping horse, writing new chapters in the vast starry sky." As a scientist-turned-taikonaut, he also made a wish for the prosperity of China's science and technology efforts, saying: "May every endeavour be rewarded."Notably, this is the fourth Spring Festival taikonauts have celebrated aboard the space station since it was completed in 2022.Though far from home, these space explorers feel the same festival warmth as people on Earth.The Shenzhou-21 trio have decorated the space station with red lanterns, Chinese knots and paper-cut craft. They will also enjoy the traditions they usually share with their families on Earth, such as eating dumplings and delicacies that stand for prosperity, peace and good fortune.Compared with previous crews, the Shenzhou-21 team has one more dish on their table: a freshly-baked cake made in the space oven.Launched on October 31, 2025, the space journey of the Shenzhou-21 crew has already exceeded 100 days. All tasks including scientific experiments, equipment maintenance and health management are progressing smoothly, according to the space agency. (Xinhua)Edited by Edmond Fong
2026-02-16 11:22:56

MicroCloud Hologram Inc. Develops GHZ State and W State Transmission Scheme Based on Brownian State Quantum Channel
SHENZHEN, China, Feb. 6, 2026 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, developed a transmission scheme for GHZ states and W states based on Brownian state quantum channels. This scheme establishes an efficient transmission mechanism for multi-particle entangled states by constructing special quantum channels and measurement systems. At the technical implementation level, HOLO uses quantum Fourier transform for quantum state projection measurement and precisely designs the sequence of quantum gate operations required for reconstructing quantum states at the receiving end. This technical scheme not only perfects the theoretical system of quantum teleportation but also provides new technical paths for information transmission in large-scale quantum systems, promoting the development of quantum communication technology toward practicalization. In terms of technical architecture design, the implementation of the Brownian state quantum channel demonstrates significant innovation. The Brownian state is a special four-particle entangled state, whose characteristics are very suitable for constructing quantum transmission channels. HOLO utilizes this entanglement characteristic to establish stable quantum links. When transmitting the three-particle GHZ state, the sender performs joint measurement on the quantum state to be transmitted and specific particles in the Brownian state, which establishes quantum correlation between the transmission state and the channel state. The key to technical implementation lies in using specially designed measurement devices to make the measurement results form a definite correspondence with the channel state. This design enables the receiver to select the corresponding quantum gate operations to reconstruct the original quantum state based on the measurement results transmitted through the classical channel. The quantum Fourier transform plays a key role in this protocol, and its technical implementation has unique advantages. The research team adopts the quantum Fourier transform to construct the basic measurement framework required for projection measurement; this method has better system adaptability compared to traditional measurement methods. Through this mathematical transformation method, researchers can map quantum states to a set of standard measurement bases, thereby achieving accurate measurement of quantum states. In actual operation, this transformation is realized through an ordered combination of a series of quantum logic gates, and its system complexity maintains a reasonable relationship with the number of qubits, ensuring the scalability of the scheme. In the design and implementation stage of quantum gate operations, HOLO has established complete technical specifications. Based on quantum mechanics principles, the research team accurately calculates all quantum gate operations that the receiving end needs to execute to reconstruct the quantum state. For the transmission of GHZ states, these operations include the combined application of specific types of phase gates and controlled-NOT gates; whereas for the transmission of W states, it is necessary to implement more complex multi-particle control operations. Technical documents show that all quantum gate operations can be represented using a standard quantum gate set; this representation method simplifies the operation process and facilitates implementation on different quantum hardware platforms. The research team has also verified the feasibility of these quantum gate operations on superconducting quantum processors; through precise regulation of the electromagnetic control signals of qubits, the required quantum logic operations can be reliably realized. From the perspective of technical application prospects, this protocol has broad application potential in the field of quantum communication. The use of quantum Fourier transform makes the construction of measurement bases more systematic and standardized, and this characteristic is advantageous for unified implementation on different quantum hardware platforms. In quantum network architectures, this protocol can be used to build core transmission modules for distributed quantum computing, realizing the transmission of quantum information between different computing nodes. In addition, HOLO has also explored application schemes for this technology in specific scenarios such as quantum secure communication and distributed quantum measurement. With the continuous advancement of quantum hardware technology, particularly the continuous improvement in qubit performance and quantity, this transmission protocol is expected to play an important role in future quantum information systems, providing key technical support for building large-scale quantum networks. About MicroCloud Hologram Inc. MicroCloud Hologram Inc. (NASDAQ: HOLO) is committed to the research and development and application of holographic technology. Its holographic technology services include holographic light detection and ranging (LiDAR) solutions based on holographic technology, holographic LiDAR point cloud algorithm architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology, providing services to customers offering holographic advanced driving assistance systems (ADAS). MicroCloud Hologram Inc. provides holographic technology services to global customers. MicroCloud Hologram Inc. also provides holographic digital twin technology services and owns proprietary holographic digital twin technology resource libraries. Its holographic digital twin technology resource library utilizes a combination of holographic digital twin software, digital content, space data-driven data science, holographic digital cloud algorithms, and holographic 3D capture technology to capture shapes and objects in 3D holographic form. MicroCloud Hologram Inc. focuses on developments such as quantum computing and quantum holography, with cash reserves exceeding 3 billion RMB, and plans to invest more than 400 million in USD from the cash reserves to engage in blockchain development, quantum computing technology development, quantum holography technology development, and derivatives and technology development in frontier technology fields such as artificial intelligence AR. MicroCloud Hologram Inc.'s goal is to become a global leading quantum holography and quantum computing technology company. Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission ("SEC"), including the Company's most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
2026-02-06 13:00:00

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals Validated system provides reliable, consistent carbon footprint data for clients INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards. The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This reflects the company's advanced and systematically developed approach to carbon accounting across biopharmaceutical manufacturing processes, supporting transparency and consistency in sustainability reporting. The validation was conducted by DNV, an independent assurance and risk management provider headquartered in Norway. DNV assessed the validity of the company's PCF system across data input, conversion, and output, confirming that the assumptions, methods, and overall approach follow globally accepted practices. Through this validated PCF framework, Samsung Biologics aims to support clearer communication and greater comparability of product-level carbon footprint data across the biopharmaceutical value chain, in line with evolving client expectations and sustainability requirements. "Achieving independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide to clients," said John Rim, President and CEO of Samsung Biologics. "This represents the company's continued focus on building sustainable operations based on established standards, while maintaining reliable and consistent manufacturing. As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration with our partners." Samsung Biologics' sustainability efforts have also been recognized through its recent EcoVadis assessment, where the company received a Platinum rating, placing it among the top one percent of companies evaluated globally for sustainability management. For more information on Samsung Biologics' sustainability efforts, please visit the company's website. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenSTM framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, visit https://samsungbiologics.com/. Media Contact Claire Kim, Senior Director cair.kim@samsung.com Becky Lee, Director brite.lee@samsung.com
2026-02-06 13:00:00

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company's Cambridge, Massachusetts office. In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico's oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company's growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies. Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials. She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration. Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth. "Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico's oncology programs," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients." "I am excited to join Insilico Medicine at such an important stage of growth," said Dr. Zhang. "Insilico's unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients." Over the past year, Insilico Medicine's oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential "best-in-class" inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy. In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico's AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor. Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround - from project initiation to preclinical candidate (PCC) nomination - of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program. About Insilico Medicine Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.
2026-02-06 13:00:00

(新春见闻)2026年粤港澳大湾区灯会亮灯调试
2月6日,粤港澳大湾区灯会《南沙花神》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《李白对月》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《青花戏律》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《星河驰骋·骏马腾云》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《大唐盛世》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《活力全运会》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄
2026-02-06 12:59:49

鸿蒙智行新款尊界 S800 申报:增程器动力升级至 127 千瓦
IT之家 2 月 6 日消息,江淮今日有两款新的尊界 S800 车型通过了工信部申报,主要是对增程器进行了升级,功率从 125 千瓦升级至 127 千瓦。外观方面,尊界 S800 采用天地人和的设计理念,纵横星瀚的全新设计语言,配备了星汉灿烂大灯、星云画卷尾灯、摘星门把手。IT之家注意到,新车尾部采用了溜背式的造型,搭配拥有星河元素的贯通式尾灯,灯组上还镶嵌了 MAEXTRO 尊界的 LOGO。工信部信息显示,新车长宽高分别为 5480mm×2000mm×1536mm,轴距为 3370mm,采用 255/45 R20、265/45 R20,265/40 R21 轮胎。两款车型总质量均为 3270kg,整备质量分别为:2700/2770/2800/2810/2830kg2804/2822/2851/2865/2870kg悬架方面,新车拥有前双叉臂,后五连杆设计。同时,还配备了双腔空气悬架、连续可变阻尼减振器、多轮转向控制。动力方面,新车将搭载 127kW 增程器(排量 1498ml),双版本电机分别为:驱动电机峰值功率(前 / 后):160kW/230kW。M8100PHD 发动机最大净功率为 122kW, 对应的油耗为 0.15L/100km (整备质量 2700kg)、0.10L/100km (整备质量 2770kg,2810kg)、0.17L/100km (整备质量 2800kg,2830kg)。驱动电机峰值功率(前 / 后左 / 后右):160kW/237.5kW/237.5kW。M8100PHD 发动机最大净功率为 122kW, 对应的油耗为 0.18L/100km (整备质量 2804kg,2822kg,2865kg)、0.23L/100km (整备质量 2851kg,2870kg)。新车将搭载 63.262kWh 电池,纯电续航:271/258km315/311/302km
2026-02-06 12:58:23

Qatar Airways Partners with Michelin One-Star Filipino Chef Jordy and May Navarra to Launch an Exclusive Business Class Menu
Available from February, the new menu brings a modern take on Filipino cuisine to Business Class passengers flying from Manila to Doha MANILA, Philippines, Feb. 2, 2026 /PRNewswire/ -- Qatar Airways is proud to announce its latest collaboration with renowned Filipino husband-and-wife duo, Chef Jordy and May Navarra, featuring an exclusive new Business Class menu for passengers travelling from Manila to Doha. Available from 2 February, the menu features a modern and refined take on well-loved Filipino dishes, and starting July 2026, the menu will also be available from Doha to Manila. Qatar Airways Partners with Michelin One-Star Filipino Chef Jordy and May Navarra to Launch an Exclusive Business Class Menu As the head chef and owner behind Manila's One-Star Michelin Restaurant, Toyo Eatery, Chef Jordy Navarra brings his passion and love for cooking to Qatar Airways, with a five-course experience that reimagines fine-dining in the skies. The menu features an appetizer of seared chilled scallops, braised beef short ribs tiyula itum for main course, pansit noodle ensalada for a light option, purée of arroz caldo for breakfast porridge and a standout dessert of sans rival cake with philippine chocolate sorbet. Ingredients are carefully sourced from local suppliers, in accordance with sustainable practices and seasonality to highlight the best Filipino ingredients. This collaboration marks another milestone in Qatar Airways' award-winning in-flight offerings and its ongoing legacy of extraordinary gourmet offerings. By investing in premium onboard experiences and joining with world-class chefs, Qatar Airways has earned a reputation as a global leader in aviation. The airline was named the 'World's Best Business Class' for the 11th time in 2024 and achieved the title of 'World's Best Airline' for a record-breaking 8th time in the same year. Synonymous with luxury and innovation, Qatar Airways also holds accolades for 'World's Best Business Class Lounge' and 'Best Airline in the Middle East'. Qatar Airways currently flies to over 170 destinations worldwide, via one seamless connection through Hamad International Airport, the 'World's Best Airport', as voted by Skytrax in 2021, 2022, and 2024. Qatar Airways x Chef Jordy and May Menu: Manila – Doha Menu Appetizer Seared Chilled Scallopmustard leaf, shrimp buro, radish and salted egg Main Course Braised Beef Short Ribs Tiyula Itumcharred coconut, eggplant and heirloom Tinawon rice Dessert Sans Rival CakePhilippine chocolate sorbet Light Option Pansit Noodle Ensaladachayote and pomelo Breakfast Porridge Puree of Arroz Caldochicken, anchovy and egg Click here to download hi-res images About Qatar AirwaysA multiple award-winning airline, Qatar Airways won the 'World's Best Airline' title for an unprecedented ninth time at the 2025 World Airline Awards, managed by the international air transport rating organisation, Skytrax. Qatar Airways was previously named the World's Best Airline in 2011, 2012, 2015, 2017, 2019, 2021, 2022, and 2024. The airline continues to be synonymous with excellence, and has yet again received recognition for 'World's Best Business Class', and 'World's Best Business Class Airline Lounge'. As the leading connector in the region, Qatar Airways has also been lauded with the 'Best Airline in the Middle East' title for the 13 time. Qatar Airways currently flies to over 170 destinations worldwide, connecting through its Doha hub, Hamad International Airport, the 'Best Airport in the Middle East' for 11 consecutive years, as well as 'World's Best Airport Shopping' for the third year in a row, as voted by Skytrax. Hamad International Airport has previously been named the 'World's Best Airport' by Skytrax in 2021, 2022, and 2024. Qatar Airways was the first Airline in the Middle East to be certified to the highest level of IATA's Environmental Assessment (IEnvA) programme, based on recognised environmental management system principles (such as ISO 14001). As an inaugural signatory to the Buckingham Palace Declaration in March 2016, Qatar Airways became the first airline globally to be certified to the industry standard for the prevention of illegal wildlife trafficking in aviation. For further information, visit www.qatarairways.com
2026-02-02 07:09:00

0.070653915405273


Yangiliklar
Yangiliklar
Xitoy
Yangiliklar
Xitoy
Yangiliklar